Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban outcomes in short bowel syndrome patients on long-term parenteral nutrition
NL-OMON48704Phase 4Recruiting
- Sponsor
- Department of Vascular Medicine of the Academic Medical Center
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in thromboembolism, sponsored by Department of Vascular Medicine of the Academic Medical Center. Primary endpoints: Recurrent venous thromboembolic events, Bleeding complications and 1 more. Started Sep 2018; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NL-OMON48704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48704.